DESENSITIZATION TO RIVAROXABAN IN A PATIENT WHO EXPERIENCED ANAPHYLACTOID SHOCK AFTER ANTICOAGULANT USE: CASE REPORT

Abstract

Case Report: Over the last two decades, new anticoagulants have been developed to prevent and manage thromboembolic diseases, including direct-acting anticoagulants like rivaroxaban, which is used for venous thromboembolism prevention, stroke prevention in atrial fibrillation, and ischemic heart disease. Here, we present the experience of a case with a history of multiple thromboses and an anaphylactoid reaction to anticoagulants, who was able to continue prophylaxis without allergic reactions after rivaroxaban desensitization.A 42-year-old female patient visited the hematology outpatient clinic to obtain a prescription for a new anticoagulant due to a supply issue with her current medication, fondaparinux.. Her medical history included thrombosis in both upper and lower extremities ten years earlier, along with heterozygous mutations for factor V Leiden and MTHFR, necessitating lifelong anticoagulant therapy. She had previously experienced anaphylactic shock from enoxaparin, warfarin, tinzaparin, and rivaroxaban, which led her to use fondaparinux without issues. When faced with a supply problem prescribed apixaban, she suffered anaphylactic shock thirty minutes after administration, requiring epinephrine treatment. Following this, the allergy and immunology department recommended a desensitization protocol for rivaroxaban, crucial for her ongoing anticoagulation. After a one-day desensitization, she successfully continued treatment with 20 mg of rivaroxaban without any allergic reactions during follow-up visits.Desensitization is a technique that allows patients with drug hypersensitivity reactions to safely maintain drug therapy by creating temporary tolerance, especially for IgE-mediated reactions. It works by inhibiting mast cell activation and reducing the release of inflammatory mediators, often resulting in decreased skin sensitivity and potentially negative skin test results after the procedure. In this case, the patient had a grade 3 early-type drug allergy, and while literature on desensitization for new-generation oral anticoagulants is scarce, the successful desensitization to rivaroxaban suggests that it may be an effective option for similar patients in the future.